Immix Biopharma Inc
NASDAQ:IMMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (16.6), the stock would be worth $-7.52 (176% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -21.8 | $9.85 |
0%
|
| Industry Average | 16.6 | $-7.52 |
-176%
|
| Country Average | 13.3 | $-6.03 |
-161%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Immix Biopharma Inc
NASDAQ:IMMX
|
521.6m USD | -21.8 | -17.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 18.5 | 84.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 18.6 | 24 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 15.9 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 30.1 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 15.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 121.3 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 12 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Immix Biopharma Inc
Glance View
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the development of therapies for patients with cancer and inflammatory diseases. The company is developing a class of tissue-specific therapeutics (TSTx) in oncology and inflammation. The Company’s lead asset, IMX-110, is is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology, which is delivered into the TME. IMX-110, is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor.
